168. Kawasaki Disease

  1. Alan D. Irvine MD, FRCPI, FRCP4,5,
  2. Peter H. Hoeger MD6,7 and
  3. Albert C. Yan MD, FAAP, FAAD8,9
  1. Wynnis L. Tom MD1,
  2. Tomisaku Kawasaki2 and
  3. Jane C. Burns3

Published Online: 24 MAY 2011

DOI: 10.1002/9781444345384.ch168

Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition

Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition

How to Cite

Tom, W. L., Kawasaki, T. and Burns, J. C. (2011) Kawasaki Disease, in Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition (eds A. D. Irvine, P. H. Hoeger and A. C. Yan), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444345384.ch168

Editor Information

  1. 4

    Trinity College, Dublin, Ireland

  2. 5

    Our Lady's Children's Hospital, Dublin, Ireland

  3. 6

    University of Hamburg, Hamburg, Germany

  4. 7

    Catholic Children's Hospital Wilhelmstift, Hamburg, Germany

  5. 8

    University of Pennsylvania School of Medicine, Philadelphia, PA, USA

  6. 9

    The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Author Information

  1. 1

    Departments of Pediatrics and Medicine (Dermatology), University of California, San Diego and Rady Children's Hospital, San Diego, CA, USA

  2. 2

    Japan Kawasaki Disease Research Center, Tokyo, Japan

  3. 3

    Rady Children's Hospital, University of California, San Diego, CA, USA

Publication History

  1. Published Online: 24 MAY 2011
  2. Published Print: 3 JUN 2011

ISBN Information

Print ISBN: 9781405176958

Online ISBN: 9781444345384



  • cardiovascular events;
  • coronary artery aneurysm;
  • exanthem;
  • intravenous immunoglobin;
  • Kawasaki disease;
  • psoriasiform


Kawasaki disease is an acute, self-limited vasculitis that mainly affects young children. Its aetiology is unknown, but its epidemiology suggests that an infectious agent triggers an intense immune response in genetically susceptible individuals. Left untreated, coronary artery lesions and aneurysms develop in about 25% of cases and can lead to thrombosis, myocardial infarction and sudden death. Intravenous immunoglobulin and aspirin therapy have markedly decreased the frequency of such complications, but the long-term outcome in adulthood remains to be determined.